0000899243-16-029936.txt : 20160923
0000899243-16-029936.hdr.sgml : 20160923
20160923183024
ACCESSION NUMBER: 0000899243-16-029936
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160921
FILED AS OF DATE: 20160923
DATE AS OF CHANGE: 20160923
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vasisht Niraj
CENTRAL INDEX KEY: 0001662930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 161900717
MAIL ADDRESS:
STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL
STREET 2: 4131 PARK LAKE AVE., SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-09-21
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001662930
Vasisht Niraj
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH
NC
27612
0
1
0
0
Chief Technology Officer
Common Stock
2016-09-21
4
A
0
4661
0.00
A
73081
D
Common Stock
2016-09-21
4
M
0
27666
0.00
A
100747
D
Common Stock
2016-09-21
4
M
0
16667
0.00
A
117414
D
Common Stock
2016-09-21
4
M
0
24980
0.00
A
142394
D
Common Stock
2016-09-21
4
M
0
66667
0.00
A
209061
D
Common Stock
2016-09-21
4
S
0
40000
2.39
D
169061
D
Common Stock
2016-09-23
4
S
0
7000
2.68
D
162061
D
Restricted Stock Units
0.00
2016-09-21
4
M
0
27666
0.00
D
2016-02-20
2016-09-21
Common Stock
27666
0
D
Restricted Stock Units
0.00
2016-09-21
4
M
0
16667
0.00
D
2016-01-30
2017-01-30
Common Stock
16667
16666
D
Restricted Stock Units
0.00
2016-09-21
4
M
0
24980
0.00
D
2016-02-22
2017-02-22
Common Stock
24980
24980
D
Restricted Stock Units
0.00
2016-09-21
4
M
0
66667
0.00
D
2016-02-23
2018-02-23
Common Stock
66667
133333
D
The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018.
The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
On September 21, 2016, the Reporting Person sold an aggregate of 40,000 shares of the Issuer's Common Stock at a weighted average price of $2.39 per share. The highest sale price for the Common Stock was $2.45 per share and the lowest sale price was $2.35 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of RSUs.
On September 23, 2016, the Reporting Person sold an aggregate of 7,000 shares of the Issuer's Common Stock at a weighted average price of $2.68 per share. The highest sale price for the Common Stock was $2.81 per share and the lowest sale price was $2.58 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Niraj Vasisht
2016-09-23